Shanghai Pharmaceuticals Holding Co (HKSE:02607) Research & Development: HK$2,556 Mil (TTM As of Mar. 2026)


HKSE:02607 Shanghai Pharmaceuticals Holding Co Ltd HKSE:02607
88 GF Score
Price HK$11.74
GF Value HK$14.54
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Pharmaceuticals Holding Co Research & Development?

Shanghai Pharmaceuticals Holding Co HKSE:02607 +2.18% 88 Research & Development is HK$2,556 Mil as of Mar. 2026. GuruFocus rates HKSE:02607 with a GF Score™ of 88/100 and a GF Value™ of HK$14.54 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shanghai Pharmaceuticals Holding Co's Research & Development for the three months ended in Mar. 2026 was HK$532 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was HK$2,556 Mil.

Shanghai Pharmaceuticals Holding Co  (HKSE:02607) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shanghai Pharmaceuticals Holding Co Research & Development Related Terms

Shanghai Pharmaceuticals Holding Co Research & Development Historical Data

* Premium members only.

The historical data trend for Shanghai Pharmaceuticals Holding Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Pharmaceuticals Holding Co Research & Development Chart

Shanghai Pharmaceuticals Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,433.36 2,358.72 2,410.73 2,556.47 2,585.07

Shanghai Pharmaceuticals Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 532.92 504.91 608.19 910.88 531.72
HKSE:02607
88GF Score
Shanghai Pharmaceuticals Holding Co Ltd HKSE:02607
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Pharmaceuticals Holding Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$2,556 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$2,556 Mil mean?
Shanghai Pharmaceuticals Holding Co (HKSE:02607) has a Research & Development of HK$2,556 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors.
Is Shanghai Pharmaceuticals Holding Co's Research & Development too high?
Shanghai Pharmaceuticals Holding Co's current Research & Development is HK$2,556 Mil. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's Research & Development compare to MCK and CAH?
Shanghai Pharmaceuticals Holding Co's Research & Development of HK$2,556 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. Shanghai Pharmaceuticals Holding Co's current Research & Development is HK$2,556 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co (HKSE:02607) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$14.54, compared to a current price of HK$11.74 — trading 19.3% below its estimated fair value. The current Research & Development is HK$2,556 Mil. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (HKSE:02607), the current Research & Development is HK$2,556 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Pharmaceuticals Holding Co (HKSE:02607) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued. The current stock price of HK$11.74 is trading 19.3% below its estimated GF Value™ of HK$14.54. GuruFocus considers Shanghai Pharmaceuticals Holding Co to be Modestly Undervalued.

Key valuation signals for HKSE:02607:

  • Research & Development: HK$2,556 Mil
  • GF Value™: HK$14.54 vs. price of HK$11.74 (19.3% below fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Pharmaceuticals Holding Co Business Description

Other Exchanges S1R:Germany601607:China
Address No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
88GF Score

Get the complete analysis for HKSE:02607

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$11.74
Price
HK$14.54
GF Value